anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to Chinese medicine composition for preventing and treating mastitis of dairy cattle and a preparation method thereof. The Chinese medicine composition comprises the following components: dandelion, selfheal spike, green tangerine peel and liquorice. The dandelion, the selfheal spike, the green tangerine peel and the liquorice are smashed and then uniformly mixed in proportion to obtain the Chinese medicine composition, the form of the Chinese medicine composition is powder. The Chinese medicine composition has the advantages of reasonable combination and preparation, simple manufacturing process, low cost, favorable taste, convenience in use, no medicine residue and no side effects. The Chinese medicine composition can be used for dairy cattle and pregnant cattle. The Chinese medicine composition provided by the invention can be used for effectively preventing and treating mastitis of dairy cattle, reducing the economic loss, and enhancing the economic benefits of the dairy cattle breading industry. The clinical tests prove that the effective rate of the Chinese medicine composition in firstly treating recessive mastitis of the dairy cattle reaches 100%, the effective rate of the Chinese medicine composition in the milk area is over 85%, and the effective rate of the Chinese medicine composition in treating clinical mastitis of the dairy cattle is over 85%. The Chinese medicine composition is suitable for preventing and treating mastitis of dairy cattle of individual farmers and scale dairy cattle fields.
Participants will be given a home exercise program consisting of exercises specifically applied to the neck. Participants will be asked to practice the exercises 5 days a week. The application status of the participants' home exercise program will be followed by the researcher over the phone. Participants who do not practice the home exercise program will be excluded from the study. The exercise program to be applied to the participants in the exercise group is listed below.Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise.
Cohort 3, healthy elderly adults, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed in the satellite group, then a further 10 healthy elderly adults will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 3).
FIELD: peptides, medicine. SUBSTANCE: invention relates to glucagon-like peptide (GLP-1), truncated GLP-1, insulinotropine and truncated insulinotropine exhibiting pI = 4.0 or less or pI = 7.0 or above. Derivatives of GLP-1, truncated GLP-1, insulinotropine and truncated insulinotropine can be used as drug for mammalian by medicinal electrophoresis administration. Invention relates to methods of insulin enhancement action in mammalian organism with mentioned above derivatives, and to pharmaceutical compositions containing such derivatives. Also, the present invention relates to new application variants of some known insulinotropine derivatives and truncated insulinotropine for insulin enhancement action in mammalian using method of medicinal electrophoresis for administration. EFFECT: improved method of synthesis, enhanced effectiveness of diabetes treatment.
Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resulted decrease in the number of tablets that a patient would need to take on a daily basis.
FIELD: medicine, oncology, pharmacy. SUBSTANCE: invention proposes to administrate intravenously ozonized physiological solution in the ozone concentration 200-400 mcg/l to patients two days before onset of chemotherapy carrying out and 4-7 times in time of its carrying out, 3-4 h before intramuscular administration of chemopreparations. Invention proposes to carry out rectal insuflations with ozone-oxygen mixture in the ozone concentration 1500-1800 mcg/ml to patients with weakly developed venous system of upper limbs two days before onset of chemotherapy and 3-4 times in time of its carrying out, 3-4 h before intramuscular administration of chemopreparations. Method allows to enhance the effectiveness of chemotherapy and to reduce frequency of complications caused by chemotherapy. Invention can be used for preoperative treatment of locally spread breast cancer. EFFECT: improved treatment method. 2 cl
PROBLEM TO BE SOLVED: To obtain a sustained release preparation which can be conveniently recovered in a high yield and possesses reduced risk in the occurrence and contamination of foreign substances by lyophilizing the sustained release preparation in a specifically pretreated tray. SOLUTION: By lyophilizing the sustained release preparation (preferably a microsphere or a microcapsule) in a vessel for lyophilization (e.g. a tray for lyophilization) of which a part or all of the inside are previously coated with an ice layer or a water repellent substrate (preferably an ethylene tetrafluoride resin, a vinylidene fluoride resin, a modified fluororesin or the like), the solid sustained release preparation is conveniently obtained in a high yield without exposure to environment over a long period of time, because the preparation obtained is hot adhered to the vessel. As the drug contained in the sustained-release preparation, a bioactive peptide, e.g. luteinization hormone-releasing hormone, insulin, somatostatin or the like, is preferably illustrated. Further, it is favorable that the ice layer formed is about 0.01-30 mm thick.
Forty-three patients requiring extraction of at least one tooth and delayed implant placement were randomly assigned to either an experimental or a control group. For both groups, demineralized freeze-dried bone allograft was used to graft the socket. For the control group, Type I bovine collagen was used as a membrane; for the experimental group, human amnion-chorion membrane was used. For both groups, the barrier membranes were left exposed, and no primary closure was achieved. Patients returned for implant placement after a mean healing period of 19.5 weeks, at which time a core bone biopsy specimen 2 mm in diameter was obtained for histomorphometric analyses. Clinical ridge dimensions were measured at the times of extraction and implant placement.
BACKGROUND: Given the inconsistencies in current studies regarding the impact of FKBP5 gene polymorphisms on depression, arising from variations in study methods, subjects, and treatment strategies, this paper provides a comprehensive review of the relationship between FKBP5 gene polymorphisms and genetic susceptibility to depression, as well as their influence on response to antidepressant treatment.
METHODS: Electronic databases were searched up to April 11, 2023, for all literature in English and Chinese on depression, FKBP5 gene polymorphisms, and antidepressant treatment. Data extraction and quality assessment were performed for key study characteristics. Qualitative methods were used to synthesize the study results.
RESULTS: A total of 21 studies were included, with the majority exhibiting average to moderate quality. Six SNPs (rs3800373, rs1360780, rs9470080, rs4713916, rs9296158, rs9394309) were broadly implicated in susceptibility to depression, while rs1360780 and rs3800373 were linked to antidepressant treatment sensitivity. Additionally, rs1360780 was associated with adverse reactions to antidepressant drug treatment. However, these associations were largely unconfirmed in replication studies.
CONCLUSIONS: Depression is recognized as a polygenic genetic disorder, with multiple genes contributing, each exerting relatively small effects. Future studies should explore not only multiple gene interactions but also epigenetic changes. Presently, research on FKBP5 in affective disorders remains notably limited, highlighting the necessity for further investigations in this domain.
Deaths have occurred in patients who received flumazenil in a variety of clinical settings. The majority of deaths occurred in patients with serious underlying disease or in patients who had ingested large amounts of non-benzodiazepine drugs (usually cyclic antidepressants), as part of an overdose.

Serious adverse events have occurred in all clinical settings, and convulsions are the most common serious adverse events reported. Flumazenil administration has been associated with the onset of convulsions in patients with severe hepatic impairment and in patients who are relying on benzodiazepine effects to control seizures, are physically dependent on benzodiazepines, or who have ingested large doses of other drugs (mixed-drug overdose). (See WARNINGS.)

Two of the 446 patients who received flumazenil in controlled clinical trials for the management of a benzodiazepine overdose had cardiac dysrhythmias (1 ventricular tachycardia, 1 junctional tachycardia).
This study aimed to assess the glycaemic response (GR), insulinaemic response (IR) and gastric emptying (GE) after the consumption of millet-based muffins in pre-diabetic and healthy participants. This was a single-blind, randomized controlled crossover study in which participants consumed one control muffin (wheat) and one test muffin (millet).This study investigated the effect of polyphenol-rich millet-based muffin on glycaemic response (GR), insulinaemic response (IR) and gastric emptying (GE) in healthy and pre-diabetic participants (people with prediabetes have blood glucose levels that are higher than normal but not yet high enough to be diagnosed as diabetes - the normal fasting blood glucose level is below 6.1 mmol/l or 108 mg/dl).

After potential participants have read the Participant Information Sheet (PIS) and signed the consent form, they were screened during the first visit to measure fasting blood glucose (FBG; fasting blood glucose should be between 6.1 to 6.9 mmol/l for pre-diabetic participants and \< 6.1 mmol/l for healthy participants ).If eligible for the study, body weight and height and blood pressure were taken in the Functional Food Centre (currently known as Oxford Brookes Centre for Nutrition and Health). If the fasting blood glucose test was less than 6.1mmol/l (participants were informed of their fasting blood glucose result and given the choice either to do Oral glucose tolerance test (OGTT) to check for Impaired Glucose Tolerance (IGT), participate in the healthy group or to be excluded). If the participant agreed to continue and had one or more of the pre-diabetes inclusion criteria, they could complete an oral glucose tolerance test (OGTT) over 2 hours.( An oral glucose tolerance test involves taking a fasting sample of blood and then taking a very sweet drink containing 75g of glucose. After having this drink participants had to stay at rest until a further blood sample is taken after 2 hours.) If their 2 h blood glucose result was between 7.9 to 11.0 mmol/l, they were considered eligible to participate in the study as a prediabetic participant, and were asked to come for a subsequent visit in order to begin the study. If the participant does not have IGT, they had the option to take part in the study as a healthy participant.
An OT practitioner will deliver the program in accordance with "Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home." Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided.
Background: Current literature demonstrates prophylactic enoxaparin to be efficacious in reducing venous thromboembolism (VTE) rates without significantly increasing risk for bleeding complications. Despite this evidence, prophylactic enoxaparin doses are frequently withheld for surgery or procedures. This exploratory study aims to quantify the risk of a VTE event in trauma patients associated with missed doses of prophylactic enoxaparin. Methods: This retrospective cohort study evaluated trauma patients admitted to our Level 1 trauma center from January 1, 2012 to January 31, 2021. A 1:1 propensity match with ten variables was performed to compare patients receiving prophylactic enoxaparin that had a VTE and those that did not. The primary outcome was a VTE event. Results: 493 patients met inclusion criteria; 1:1 propensity score matching was performed resulting in a cohort of 184 patients. The percentage of patients that missed a prophylactic enoxaparin dose in the VTE group was higher than the no VTE group (34.8% vs 21.7%, P = 0.049). This is consistent when examining total missed doses (P = 0.038) and consecutively missed doses (P = 0.035). The odds of having a VTE for patients that missed at least one dose or more of enoxaparin are nearly two times greater (OR 1.92, 95% CI 0.997, 3.7). Conclusion: Missing enoxaparin doses significantly increases the risk of VTE in matched populations. Most prophylactic enoxaparin doses were held for procedures, and not for bleeding events. Trauma teams should carefully weigh the risk of bleeding complications associated with continuing enoxaparin prophylaxis against the significant thromboembolic risk of withholding it.
Selenium is essential for the synthesis and function of various selenoenzymes, such as glutathione peroxidases, selenoprotein P, and thioredoxin reductase. These enzymes play a critical role in both antioxidant defense and in limiting oxidative damage. Numerous studies have reported associations between serum selenium concentration, obstetric complications and pregnancy outcomes. The aim of this study was to determine whether the dietary intake of selenium, its serum concentration, and the activity of glutathione peroxidase in subsequent trimesters of pregnancy affect the birth condition of newborns. This was assessed based on the APGAR score in the 1st and 5th minute of life, birth weight, body length and head and chest circumference in both physiological and complicated pregnancy courses. Twenty-seven pregnant women, with a mean age of 29.6 ± 4.8 years from the Lower Silesia region of Poland, participated in the study. Fifty-five percent of the study group experienced pregnancy complications. The median reported selenium intake and serum selenium content for Polish pregnant women in the first trimester was 56.30 μg/day and 43.89 μg/L, respectively. These figures changed in the second trimester to 58.31 μg/day and 41.97 μg/L and in the third trimester to 55.60 μg/day and 41.90 μg/L. In the subgroup of pregnant women with a physiological pregnancy course, a weak, positive correlation was observed in the first trimester between Se intake and the length (R = 0.48, p = 0.019) and the birth weight of newborns (R = 0.472, p = 0.022). In the second trimester, a positive correlation was noted with the APGAR score at the 1st (R = 0.680, p = 0.005) and 5th minutes (R = 0.55, p = 0.033), and in the third trimester with the APGAR score at the 1st minute (R = 0.658, p = 0.019). The glutathione peroxidase activity had a strong positive correlation with the APGAR score at the 1st min (R = 0.650, p = 0.008) in the second trimester and with the birth weight of the newborns (R = 0.598, p = 0.039) in the third trimester. No correlation was found between newborns' birth measurements and serum selenium concentration. In the subgroup of pregnant women with complications, a strong, negative correlation was found between Se intake in the second trimester and gestational age (R = -0.618, p = 0.032). In the third trimester, a positive correlation was noted between Se concentration in serum and head circumference (R = 0.587, p = 0.021). The results indicate that maternal selenium status during pregnancy, including dietary intake, serum concentration, and glutathione peroxidase activity, correlates with anthropometric parameters of the newborn, such as birth weight, length, and APGAR score, especially in pregnancies with a physiological course. However, these relationships diminish in importance when pregnancy complications occur.
BACKGROUND: Calcium (Ca2+) uptake by mitochondria occurs via the mitochondrial Ca2+ uniporter. Mitochondrial Ca2+ uniporter exists as a complex, regulated by 3 MICU (mitochondrial Ca2+ uptake) proteins localized in the intermembrane space: MICU1, MICU2, and MICU3. Although MICU3 is present in the heart, its role is largely unknown.
METHODS: We used CRISPR-Cas9 to generate a mouse with global deletion of MICU3 and an adeno-associated virus (AAV9) to overexpress MICU3 in wild-type mice. We examined the role of MICU3 in regulating mitochondrial calcium ([Ca2+]m) in ex vivo hearts using an optical method following adrenergic stimulation in perfused hearts loaded with a Ca2+-sensitive fluorophore. Additionally, we studied how deletion and overexpression of MICU3, respectively, impact cardiac function in vivo by echocardiography and the molecular composition of the mitochondrial Ca2+ uniporter complex via Western blot, immunoprecipitation, and Blue native-PAGE analysis. Finally, we measured MICU3 expression in failing human hearts.
RESULTS: MICU3 knock out hearts and cardiomyocytes exhibited a significantly smaller increase in [Ca2+]m than wild-type hearts following acute isoproterenol infusion. In contrast, heart with overexpression of MICU3 exhibited an enhanced increase in [Ca2+]m compared with control hearts. Echocardiography analysis showed no significant difference in cardiac function in knock out MICU3 mice relative to wild-type mice at baseline. However, mice with overexpression of MICU3 exhibited significantly reduced ejection fraction and fractional shortening compared with control mice. We observed a significant increase in the ratio of heart weight to tibia length in hearts with overexpression of MICU3 compared with controls, consistent with hypertrophy. We also found a significant decrease in MICU3 protein and expression in failing human hearts.
CONCLUSIONS: Our results indicate that increased and decreased expression of MICU3 enhances and reduces, respectively, the uptake of [Ca2+]m in the heart. We conclude that MICU3 plays an important role in regulating [Ca2+]m physiologically, and overexpression of MICU3 is sufficient to induce cardiac hypertrophy, making MICU3 a possible therapeutic target.
The invention relates to a health care cola and provides health-care cola with the function of preventing hyperlipidemia. The health-care cola comprises the following components in parts by weight: 10-30 parts of Ficus erecta Thunb. var. liquid extract, 200-300 parts of granulated sugar, 2.5-3 parts of phosphoric acid, 0.3-0.4 part of caffeine, 0.04-0.06 part of tea polyphenol and 4-5 parts of cola essence, wherein the Ficus erecta Thunb. var. liquid extract is prepared by adding defined amount of water to Ficus erecta Thunb. var. and liquorice in a ratio of (10-20):(0.2-1); and the health-care cola is prepared according to the existing cola production process. The health-care cola conditions the balance among livers, spleens and kidneys, quenches thirst, disperses blood stasis, removes turbidity, relaxes muscles, stimulates blood circulation and dredges collaterals via Ficus erecta Thunb. var. and semen cuscutae, thus achieving the aim of reducing blood lipid.
This invention provides a useful protein-bound magnetic particle which includes a magnetic particle produced in the cell of a magnetic bacterium, and a hybrid protein bound to an organic membrane covering the magnetic particle, and of which the hybrid protein comprises a membrane protein which is originally produced in a state of being bound to the organic membrane, and one or more useful proteins bound biologically through fusion or other binding means to the membrane protein. The protein biologically immobilized does not suffer reduced activity. It is possible to obtain a useful protein such as an enzyme, antibody, etc. immobilized on a magnetic particle, only by cultivating a transformed bacterium, and separating a magnetic particle produced in the cell of the bacterium. When a functional protein is immobilized in this way, it is possible to guide the functional protein magnetically, and to move it to a desired location effectively. As the expression site of a protein can be controlled genetically, a magnetic particle on which a binding protein such as protein A and a labeling protein such as luminescence-related protein are allowed to express themselves close to each other enables a highly sensitive detection process.
The present invention relates to a Chinese medicine for preventing and curing cholera. It is made up by using the Chinese medicinal materials of evodia fruit, katsumada's galangal seed, turmeric, galangal root and licorice according to a certain mixing ratio. It can be made into powder or pill preparation. As compared with existent technology, it possesses the advantages of quickly-obtaining obvious therapeutic effect, convenient administration, and low cost, etc. Besides, it also possesses the functions of resolving toxin, dispersing food and transforming stagnation, dissipating cold, stopping pain, downbearing counterflow and checking vomiting, etc. and can be used for curing the diseases of coliinfection, liquor, fish and meat poisoning, vomiting and diarrhea and dyspepsia, etc.
Injectable platelet-rich fibrin was prepared by centrifuging venous blood samples from women with stress urinary incontinence. The obtained autologous material was injected into the anterior vaginal wall, approximately 1.5 cm below the urethral meatus, without applying a local anesthetic. The procedure was repeated for the same patient three times with an interval of one month. The severity of urinary incontinence was evaluated by filling out questionnaires before and after the procedure.